Latest Intellectual Property News

Patrys has assigned its deoxymab intellectual property to Yale University in a deal granting it half of all future commercialisation revenue, reducing capital needs while keeping long-term upside.

Mesoblast Limited’s Ryoncil® posted US$36 million in Q4 revenue, driving a full-year total of US$115 million, exceeding initial forecasts. The FDA-approved stem cell therapy for pediatric graft-versus-host disease shows robust uptake across US pediatric centres.

Archer Materials made significant strides in quantum chip fabrication and quantum neural network fraud detection, while progressing its Biochip beta prototype. A $7 million placement post-quarter strengthens its financial position to accelerate development and commercialisation.

Locksley Resources has demonstrated significant progress in antimony recovery through its collaboration with Rice University, successfully upgrading raw ore to high-purity antimony products and producing metallic antimony via electrodeposition.

Proteomics International has won a key US patent for its PromarkerEndo blood test, bolstering its commercial foothold in the world’s largest healthcare market. The patented technology offers a non-invasive, accurate diagnosis of endometriosis, a condition that currently takes years to detect.

Temas Resources has filed a new patent for its proprietary Regenerative Chloride Leach (RCL) process targeting vanadium extraction, broadening its critical minerals technology portfolio and reinforcing its commercial licensing ambitions.

ION Video Limited (ASX: IOV) reported its first-ever positive operating cash flow of $179,847 for the June quarter, eliminated $2.65 million of debt through Convertible Note conversion, and expanded its patent portfolio to five families while advancing its Virtual Video platform technology.

Argent BioPharma has struck a global licensing deal for its CannEpil® epilepsy therapy with Splash Beverage Group, securing US$5.5 million upfront through convertible debt forgiveness and retaining manufacturing and intellectual property rights alongside a 15% royalty on future sales.

Botanix Pharmaceuticals has received an Intention to Grant from the European Patent Office for a patent protecting its Sofdra applicator technology, potentially extending exclusivity in Europe until 2039.

Foresta Group Holdings has received allowance from the USPTO for its US patent application covering its proprietary rosin and terpene production process, expected to protect its technology until at least 2041.

Pure Resources has achieved peer-reviewed validation and in-house production of carbon nanotube fibre fabrics, demonstrating directional heat routing capabilities that could redefine thermal management in data centres and defence electronics.

Algorae Pharmaceuticals has independently validated its AlgoraeOS v2 platform, confirming improved accuracy in predicting synergistic drug combinations involving CBD across cancer models.